Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Q2 Revenue Jumps 10 Percent as Profit Surges 69 Percent; Shares Climb 6 Percent

NEW YORK (GenomeWeb News) – Bruker Biosciences today reported that total revenues for the second quarter increased nearly 10 percent as net income jumped 69 percent.
The report caused shares in Bruker to trade up 6 percent, or $.35, at $5.86 in mid-afternoon trading.
Receipts for the three months ended June 30 increased to $78 million from $71 million year over year.
R&D costs declined 3 percent to $10.6 million from $11 million from the comparable quarter a year ago.
The company said net income increased to $480,000 from $284,000 during the comparable period last year.
Bruker said it had around $96.6 million in cash and cash equivalents as of June 30.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.